GZMB - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	NEK9	NIMA related kinase 9	Activation of NIMA Kinases NEK9, NEK6, NEK7 Nuclear Pore Complex (NPC) Disassembly EML4 and NUDC in mitotic spindle formation	Fostamatinib
	BID	BH3 interacting domain death agonist	Activation of BAD and translocation to mitochondria Activation and oligomerization of BAK protein BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Activation, translocation and oligomerization of BAX TP53 Regulates Transcription of Genes Involved in Cytochrome C Release Activation, myristolyation of BID and translocation to mitochondria
	CASP3	caspase 3	Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes Apoptotic cleavage of cellular proteins SMAC, XIAP-regulated apoptotic response Apoptosis induced DNA fragmentation Degradation of the extracellular matrix Signaling by Hippo NADE modulates death signalling Stimulation of the cell death response by PAK-2p34 Caspase-mediated cleavage of cytoskeletal proteins Apoptotic cleavage of cell adhesion proteins Caspase activation via Dependence Receptors in the absence of ligand Caspase activation via Dependence Receptors in the absence of ligand Other interleukin signaling Pyroptosis CASP4-mediated substrate cleavage CASP5-mediated substrate cleavage	Pamidronic acid Acetylsalicylic acid Minocycline 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid Emricasan Incadronic acid 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide Tributyrin Oleandrin PAC-1 Glycyrrhizic acid
	CASP7	caspase 7	Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes Apoptotic cleavage of cellular proteins SMAC, XIAP-regulated apoptotic response Caspase-mediated cleavage of cytoskeletal proteins	Fica Emricasan Incadronic acid
	CASP8	caspase 8	Apoptotic cleavage of cellular proteins Caspase activation via Death Receptors in the presence of ligand NOD1/2 Signaling Pathway TRIF-mediated programmed cell death Caspase-mediated cleavage of cytoskeletal proteins Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling CLEC7A/inflammasome pathway Regulation of necroptotic cell death Dimerization of procaspase-8 Activation, myristolyation of BID and translocation to mitochondria Apoptotic execution phase FasL/ CD95L signaling TRAIL signaling TLR3-mediated TICAM1-dependent programmed cell death NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Microbial modulation of RIPK1-mediated regulated necrosis Defective RIPK1-mediated regulated necrosis Regulation of NF-kappa B signaling	Trichostatin A AN-9 Bryostatin 1 Bardoxolone Oleandrin	Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
	CASP9	caspase 9	Formation of apoptosome Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes NOD1/2 Signaling Pathway AKT phosphorylates targets in the cytosol Caspase activation via Dependence Receptors in the absence of ligand Constitutive Signaling by AKT1 E17K in Cancer Regulation of the apoptosome activity Regulation of the apoptosome activity	Pamidronic acid
	CD2AP	CD2 associated protein	Nephrin family interactions		Nephrotic syndrome and focal segmental glomerulosclerosis
	CHRM3	cholinergic receptor muscarinic 3	Muscarinic acetylcholine receptors Acetylcholine regulates insulin secretion G alpha (q) signalling events	Cevimeline Tramadol Succinylcholine Trospium Ziprasidone Disopyramide Amitriptyline Ipratropium Olanzapine Metixene Terfenadine Clozapine Doxylamine Trihexyphenidyl Oxyphencyclimine Procyclidine Loxapine Carbamoylcholine Hyoscyamine Cyproheptadine Meperidine Imipramine Methscopolamine bromide Chlorpromazine Darifenacin Haloperidol Tridihexethyl Anisotropine methylbromide Nortriptyline Amoxapine Cinnarizine Atropine Thiopental Nicardipine Paroxetine Homatropine methylbromide Trimipramine Scopolamine Benzquinamide Propiomazine Dicyclomine Tropicamide Brompheniramine Maprotiline Methantheline Glycopyrronium Bethanechol Tolterodine Oxybutynin Promethazine Pilocarpine Doxepin Desipramine Ketamine Quetiapine Mivacurium Diphenidol Aripiprazole Chlorprothixene Pancuronium Pipecuronium Methotrimeprazine Tiotropium Solifenacin Isopropamide Acetylcholine Arecoline Mepenzolate ALKS 27 Pizotifen Fesoterodine Methacholine Hexocyclium Aclidinium Umeclidinium Trimebutine Dosulepin Viloxazine Etoperidone Imidafenacin Butylscopolamine Homatropine Thonzylamine Revefenacin Propiverine Rociverine Diphemanil Aripiprazole lauroxil
	DFFA	DNA fragmentation factor subunit alpha	Apoptosis induced DNA fragmentation
	GRIA3	glutamate ionotropic receptor AMPA type subunit 3	Activation of AMPA receptors Trafficking of AMPA receptors Trafficking of GluR2-containing AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Synaptic adhesion-like molecules	Glutamic acid Butabarbital Ethanol Lithium cation Aniracetam Talampanel CX-717 Fluciclovine (18F) Lithium citrate Lithium succinate Lithium carbonate	Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
	IGF2R	insulin like growth factor 2 receptor	Golgi Associated Vesicle Biogenesis Neutrophil degranulation Retrograde transport at the Trans-Golgi-Network Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Mecasermin alpha-D-mannose 6-phosphate Cerliponase alfa Mecasermin rinfabate Avalglucosidase alfa	Hepatocellular carcinoma
	LMNA	lamin A/C	XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions		Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
	LMNB1	lamin B1	Meiotic synapsis Formation of Senescence-Associated Heterochromatin Foci (SAHF) Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina Depolymerization of the Nuclear Lamina Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation RHOD GTPase cycle RHOF GTPase cycle
	PARP1	poly(ADP-ribose) polymerase 1	POLB-Dependent Long Patch Base Excision Repair vRNA Synthesis Downregulation of SMAD2/3:SMAD4 transcriptional activity SUMOylation of DNA damage response and repair proteins HDR through MMEJ (alt-NHEJ) DNA Damage Recognition in GG-NER Formation of Incision Complex in GG-NER Dual Incision in GG-NER	Theophylline Zinc Carba-nicotinamide-adenine-dinucleotide NU1025 Nicotinamide 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone 3-Methoxybenzamide 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide 3,4-Dihydro-5-Methyl-Isoquinolinone 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE Veliparib A-620223 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE Olaparib Talazoparib Niraparib Rucaparib Iniparib Zinc acetate Zinc chloride Zinc sulfate, unspecified form
	PRF1	perforin 1	Nuclear events stimulated by ALK signaling in cancer		Familial hemophagocytic lymphohistiocytosis (FHPL), including the following three diseases: Perforin deficiency; Munc deficiency; STX11 deficiency
	PRKDC	protein kinase, DNA-activated, catalytic subunit	Cytosolic sensors of pathogen-associated DNA IRF3-mediated induction of type I IFN Nonhomologous End-Joining (NHEJ) E3 ubiquitin ligases ubiquitinate target proteins	Caffeine SF1126
	PTGES3	prostaglandin E synthase 3	Synthesis of Prostaglandins (PG) and Thromboxanes (TX) HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand HSF1 activation Attenuation phase Aryl hydrocarbon receptor signalling ESR-mediated signaling Estrogen-dependent gene expression Potential therapeutics for SARS	Acetaminophen Grn163l Copper
	PTK2	protein tyrosine kinase 2	Apoptotic cleavage of cellular proteins Regulation of actin dynamics for phagocytic cup formation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Signal regulatory protein family interactions EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling DCC mediated attractive signaling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway RHO GTPases Activate WASPs and WAVEs RAF/MAP kinase cascade MET activates PTK2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling FCGR3A-mediated phagocytosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Endostatin 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE Fostamatinib
	RAB27A	RAB27A, member RAS oncogene family	Insulin processing Neutrophil degranulation RAB geranylgeranylation RAB GEFs exchange GTP for GDP on RABs Regulation of MITF-M-dependent genes involved in pigmentation		Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
	SERPINB9	serpin family B member 9		Raloxifene

Search Results for: GZMB